恩度联合含铂类化疗方案治疗晚期非小细胞肺癌胸腔积液急性 发作的临床疗效观察  

Clinical effect of ENDOSTAR combined with platinumbased chemotherapy on advanced non-small cell lung cancer patients with pleural effusion in acute episode

作　　者：卢宏全 黄国定[1] 潘敏丽[1] 林影[1] 

机构地区：[1]儋州市第一人民医院肿瘤内科,海南儋州571700

出　　处：《临床与病理杂志》2016年第10期1652-1657,共6页Journal of Clinical and Pathological Research

摘　　要：目的:观察恩度联合含铂类化疗方案治疗晚期非小细胞肺癌胸腔积液急性发作的临床疗效。方法:选择2014年3月至2016年1月在我院接受治疗的晚期非小细胞肺癌胸腔积液急性发作患者1 0 0例,按照随机抽签的方式将其分为观察组和对照组,对照组患者给予单纯的含铂类化疗,观察组则给予恩度联合含铂类化疗,治疗结束后,观察两组的临床疗效。结果:治疗后,观察组的总缓解率为88%、生活质量总改善率为82%,明显的高于对照组的总缓解率56%、总改善率4 4%,两组比较差异具有统计学意义(P<0.0 5);治疗后,观察组胸水V EG F、H I F-1α水平分别为(3 3 4.7±8 1.4)p g/m L、(4 2.7±3.9)n g/L明显的低于对照组胸水V EG F水平(4 5 1.7±9 3.2)p g/m L、HIF-1α水平(48.9±3.2)ng/L,且观察组的肿瘤标记物水平明显的低于对照组,两组比较差异具有统计学意义(P<0.05);观察组在治疗期间总共发生69人次不良反应,对照组总共发生68人次不良反应,两组比较无显著差异(P>0.05)。结论:恩度联合含铂类化疗方案治疗晚期非小细胞肺癌胸腔积液急性发作具有显著的临床效果,有效地降低患者胸水VEGF、HIF-1α水平,且不会增加不良反应的发生。Objective：To study the clinical effect of ENDOSTAR combined with platinum-based chemotherapy on advanced non-small cell lung cancer with pleural effusion in acute episode. Methods：Selected 100 patients with advanced non-small cell lung cancer with pleural effusion acute episodes from March 2014 to January 2014 in our hospital, according to the random lottery, divided the patients into the observation group and control group, control group patients given pure of platinum-based chemotherapy, observation group were given ENDOSTAR combined with platinum-based chemotherapy treatment, and after the treatment, observed the clinical curative effect in both groups. Results： After treatment, the overall remission rate of observation group was 88%, the total quality of life period was 82%, which were both significantly higher than those in control group with response rate （56%）, quality of life （44%）, the differences were statistically significant （P〈0.05）; after treatment, the hydrothorax VEGF, HIF-1α level in the observation group were respectively （334.7±81.4） pg/mL and （42.7±3.9） ng/L, which were significantly lower than those in the control group with hydrothorax VEGF level （451.7±93.2） pg/mL, HIF-1α level （48.9±3.2） ng/L; and tumor markers level of observation group was obviously lower than that of the control group, the difference were statistically significant （P〈0.05）; 69 patients had adverse reactions during treatment in the observation group, while 68 had in control group, the difference had no significant difference （P〉0.05）. Conclusion： ENDOSTAR combined platinum-based chemotherapy on advanced non-small cell lung cancer patients with pleural effusion in acute episode has significant clinical effect, effectively reduces pleural effusion VEGF, HIF-1α level, and will not increase the occurrence of adverse reactions.

关 键 词：恩度 非小细胞肺癌 胸腔积液 联合化疗 

分 类 号：R734.2[医药卫生—肿瘤]